Abstract 4641: Development of modified dosing approaches to achieve specific pharmacokinetic (PK) objectives in the first-in-human phase I clinical trial of IMGN853, a folate receptor α-targeting antibody drug conjugate

Mapping Intimacies ◽

10.1158/1538-7445.am2014-4641 ◽

2014 ◽

Author(s):

Jose F. Ponte ◽

Kelli L. Running ◽

Maurice Kirby ◽

Julie Chan ◽

Jan Pinkas ◽

...

Keyword(s):

Clinical Trial ◽

Phase I ◽

Folate Receptor ◽

Phase I Clinical Trial ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Abstract P5-19-27: IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552)

10.1158/1538-7445.sabcs14-p5-19-27 ◽

2015 ◽

Cited By ~ 4

Author(s):

Aditya Bardia ◽

Alexander Starodub ◽

Rebecca L Moroose ◽

Ingrid A Mayer ◽

Jennifer R Diamond ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Phase I ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Antibody Drug ◽

Novel Therapeutic

Download Full-text

Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5518 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5518-5518 ◽

Cited By ~ 5

Author(s):

Kathleen N. Moore ◽

Lainie P. Martin ◽

Shelly Marie Seward ◽

Todd Michael Bauer ◽

David M. O'Malley ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Epithelial Ovarian Cancer ◽

Phase I Trial ◽

Folate Receptor ◽

Single Agent ◽

Antibody Drug Conjugate ◽

Receptor Alpha ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.08.015 ◽

2017 ◽

Vol 147 (2) ◽

pp. 402-407 ◽

Cited By ~ 24

Author(s):

Lainie P. Martin ◽

Jason A. Konner ◽

Kathleen N. Moore ◽

Shelly M. Seward ◽

Ursula A. Matulonis ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Epithelial Ovarian Cancer ◽

Cancer Patients ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Receptor Alpha ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

PHASE I EXPANSION STUDY OF MIRVETUXIMAB SORAVTANSINE, A FOLATE RECEPTOR ALPHA (FRa)-TARGETING ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH ENDOMETRIAL CANCER

10.26226/morressier.59ba7298d462b80296ca210c ◽

2017 ◽

Author(s):

Lainie Martin

Keyword(s):

Endometrial Cancer ◽

Phase I ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Case Medical Research ◽

10.31525/ct1-nct04300556 ◽

2020 ◽

Author(s):

Keyword(s):

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Tumor Types ◽

Antibody Drug

Download Full-text

Abstract PS10-51: TAA013 a trastuzumab antibody drug conjugate phase I dose escalation study in recurrent her2 positive breast cancer

10.1158/1538-7445.sabcs20-ps10-51 ◽

2021 ◽

Author(s):

J M Liu ◽

Y M Yin ◽

Hao Wu ◽

W Li ◽

X Huang ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Dose Escalation ◽

Antibody Drug Conjugate ◽

Her2 Positive ◽

Dose Escalation Study ◽

Drug Conjugate ◽

Her2 Positive Breast Cancer ◽

Antibody Drug ◽

Positive Breast Cancer

Download Full-text

FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

Annals of Oncology ◽

10.1093/annonc/mdz250 ◽

2019 ◽

Vol 30 ◽

pp. v403 ◽

Cited By ~ 8

Author(s):

K. Moore ◽

A. Oza ◽

N. Colombo ◽

A. Oaknin ◽

G. Scambia ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Phase Iii ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Phase Iii Study ◽

Antibody Drug

Download Full-text

5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70912-7 ◽

2009 ◽

Vol 7 (2) ◽

pp. 266-267 ◽

Cited By ~ 1

Author(s):

H. Burris ◽

S. Vukelja ◽

I. Krop ◽

S. Modi ◽

B. Klencke ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase I ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Antibody Drug Conjugate ◽

Safety And Efficacy ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Abstract C023: IKS01, a next generation antibody drug conjugate, shows target-dependent efficacy in a platinum-resistant tumor model with low levels of folate receptor α expression

10.1158/1535-7163.targ-19-c023 ◽

2019 ◽

Author(s):

Jenny Thirlway ◽

Adam Lodge ◽

Andria Pelava ◽

Daniel J Williamson ◽

Davide Carta ◽

...

Keyword(s):

Folate Receptor ◽

Tumor Model ◽

Next Generation ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Platinum Resistant ◽

Low Levels ◽

Antibody Drug

Download Full-text

Abstract 1770: Morab-202, a folate receptor alpha-targeted antibody-drug conjugate, shows a highly potent activity against a panel of FRA-expressing tumors

10.1158/1538-7445.am2018-1770 ◽

2018 ◽

Author(s):

Caroline Mignard ◽

Coralie DURIX ◽

Katherine Rybinski ◽

Xin Cheng ◽

Keiji Furuuchi ◽

...

Keyword(s):

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text